Skip to content
Menu
Blythe Adamson, PhD, MPH
  • Infectious Economics LLC
  • Publications
    • Manuscripts
    • Abstracts
    • Other Articles
    • Speaking
  • Courses
    • Short Course
    • Methods
    • Research
    • Resources
  • Media
    • Press
    • Speaking
  • About
Blythe Adamson, PhD, MPH
June 24, 2018November 1, 2018

Economic Impact of Comparative-Effectiveness Studies

@AcademyHealth #ARM2018 attendees: join me on Monday at 3:15 pm in room 605-606, where Anirban Basu will present our work in collaboration with the Patient Centered Outcomes Research Institute (PCORI) to quantify the potential economic impact of the findings from comparative-effectiveness research studies.

Goal

Our goal was to understand the potential benefits of implementing comparative-effectiveness research findings. We developed a common modeling framework across multiple disease conditions and interventions to estimate the impact for different stakeholders. This will not be a conversation about value… but enumerating costs and consequences.

Common Modeling Framework

Conceptual diagram of common model to evaluate the impact of comparative-effectiveness studies using population cohorts (left) and a simplified representation of decision-model structure (right).

Impact

We developed four economic models to evaluate the potential impact of four studies selected by PCORI:

  1. Antibiotics administered intravenously via a peripherally inserted central venous catheter (PICC) or orally for post-discharge treatment of children with acute osteomyelitis or complicated pneumonia using
  2. Warfarin versus to anticoagulation among anticoagulation naïve elderly acute ischemic stroke patients, who are discharged alive with documented persistent or paroxysmal atrial fibrillation/flutter
  3. Use of self-monitor blood glucose (SMBG) for non-insulin-treated patients with type 2 diabetes
  4. Shared decision-making using a decision aid with usual care in the choice of admission for observation and further cardiac testing or for referral for outpatient evaluation in patients with possible acute coronary syndrome

Presentation Details

  • Session: “Implementing PCOR Results to Inform Choices and Improve Healthcare Delivery”
  • Time: Monday, June 25, 2018 3:15 PM – 4:45 PM
  • Location: Room 605-606, Washington State Convention Center, Seattle, WA

Stay tuned for more details that will become available soon in a full-length manuscript.  

Disclosure

These are results from joint work I conducted with Anirban Basu, in collaboration with PCORI research staff, Joanna Siegel and William Lawrence. The work carried out under Salutis Consulting LLC and funded by PCORI.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Top Posts & Pages

  • Course
    Course
  • RWE accuracy of rapid antigen vs PCR tests for infectious Omicron
    RWE accuracy of rapid antigen vs PCR tests for infectious Omicron
  • ACA Medicaid expansion eliminated racial disparities in timely cancer treatment
    ACA Medicaid expansion eliminated racial disparities in timely cancer treatment
  • About
    About
My Tweets
Twitter

Top Posts & Pages

  • Course
    Course
  • RWE accuracy of rapid antigen vs PCR tests for infectious Omicron
    RWE accuracy of rapid antigen vs PCR tests for infectious Omicron
  • ACA Medicaid expansion eliminated racial disparities in timely cancer treatment
    ACA Medicaid expansion eliminated racial disparities in timely cancer treatment
  • About
    About
My Tweets
©2022 Blythe Adamson, PhD, MPH | Powered by WordPress and Superb Themes!
 

Loading Comments...